Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $105 to $111.